Inbiomotion validates its test, which will help reduce mortality in breast cancer

Inbiomotion, a spin-off from IRB Barcelona, developed a unique single-gene-based biomarker for the personalised adjuvant treatment of early-stage breast cancer patients. The study has compared the clinical efficacy of the proprietary MAFTEST® for the selection of patients for adjuvant bisphosphonate therapy with that of current clinical guidance.

The MAFTEST® assessments of the landmark clinical trials NSABP-B34 and AZURE showed its clinical value for the selection of individuals with early-stage breast cancer who can benefit from adjuvant clodronate treatment. The study shows that stratification of early-stage breast cancer patients according to MAF status reduces the risk of death and relapse in MAF-negative patients by 26% and 23%, respectively, compared to a 12% and 15% reduction in the risk of death or relapse seen with stratification by menopausal status, recommended by current ESMO and ASCO Clinical Guidelines.

The use of MAF status for selecting early-stage breast cancer patients for bisphosphonate treatment allows young premenopausal patients currently excluded by existing clinical guidance access to therapy.

For more information:

Thank you!

We would like to thank all the people and institutions who have made 2022 an exceptional year. Thanks to your contributions, our science is bringing about biomedical breakthroughs that have an increasing impact on people's lives. We would also like to thank all the people and organisations who have joined the Metastasis Challenge.

Every donation, every event, every legacy helps us get one step closer to our goal of stopping metastasis.